# Andy Hu

> Andy Hu is a physician-turned-dealmaker who serves as Chief Business Officer of Augustine Therapeutics, a Leuven and Cambridge biotech advancing next-generation selective HDAC6 inhibitors for neuromuscular, neurodegenerative, and cardio-metabolic diseases. He joined permanently in April 2025 after a stint as advisor, fresh off serving as CBO of Arkuda Therapeutics through its acquisition by Johnson & Johnson. Trained as an MD at Baylor with an MBA from Rice and an undergraduate degree from Harvard, Hu has built a career steering life sciences companies through IPOs, partnerships, and acquisitions - from Dimension Therapeutics to Ultragenyx, plus stints in investment banking at Leerink Partners and consulting at Strategic Decisions Group.

- **Role:** Chief Business Officer at Augustine Therapeutics
- **Organizations:** Augustine Therapeutics, Arkuda Therapeutics, Dimension Therapeutics, Cubist Pharmaceuticals, Leerink Partners, Strategic Decisions Group
- **Nationality:** American
- **Education:** AB in Environmental Science and Public Policy, Harvard University, MD, Baylor College of Medicine, MBA, Jones Graduate School of Management, Rice University
- **Known for:** Served as Chief Business Officer of Arkuda Therapeutics through its acquisition by Johnson & Johnson (announced January 2025), Helped lead Dimension Therapeutics through an IPO, multiple strategic partnering transactions, and acquisition by Ultragenyx, Part of investment banking teams at Leerink Partners that executed over $600 million in equity financings for life sciences companies

## Career timeline

- **—** — Senior consultant at Strategic Decisions Group, advising major biopharma companies on strategy
- **—** — Investment banking at Leerink Partners, executing over $600 million in equity financings for public and private life sciences companies
- **—** — Senior Vice President, Business Development at Dimension Therapeutics; helped guide the company through IPO, strategic partnerships, and acquisition by Ultragenyx
- **2025** — Chief Business Officer at Arkuda Therapeutics through its acquisition by Johnson & Johnson, announced January 2025
- **2025** — Appointed Chief Business Officer of Augustine Therapeutics in April 2025 after serving as an advisor

## Achievements

- Served as Chief Business Officer of Arkuda Therapeutics through its acquisition by Johnson & Johnson (announced January 2025)
- Helped lead Dimension Therapeutics through an IPO, multiple strategic partnering transactions, and acquisition by Ultragenyx
- Part of investment banking teams at Leerink Partners that executed over $600 million in equity financings for life sciences companies
- Joined Augustine Therapeutics shortly after its oversubscribed €78M / $85M Series A round

## Latest updates

- **2025-04** — Appointed Chief Business Officer of Augustine Therapeutics, joining permanently after serving as an advisor.
- **2025-01** — Arkuda Therapeutics, where Hu was Chief Business Officer, was acquired by Johnson & Johnson.

## Links

- Website: https://augustinetx.com
- LinkedIn: http://www.linkedin.com/in/andythu

---

Profile page: https://yespress.io/andy-hu
Published by YesPress — https://yespress.io
Last updated: 2026-06-14